Effects of branched-chain amino acid (BCAA) supplementation on the progression of advanced liver disease: A korean nationwide, multicenter, prospective, observational, cohort study

Jung Gil Park; Won Young Tak; Soo Young Park; Young Oh Kweon; Woo Jin Chung; Byoung Kuk Jang; Si Hyun Bae; Heon Ju Lee; Jae Young Jang; Ki Tae Suk; Myung Jin Oh; Jeong Heo; Hyun Young Woo; Se Young Jang; Yu Rim Lee; June Sung Lee; Do Young Kim; Seok Hyun Kim; Jeong Ill Suh; In Hee Kim; Min Kyu Kang; Won Kee Lee

doi:10.3390/nu12051429

Effects of branched-chain amino acid (BCAA) supplementation on the progression of advanced liver disease: A korean nationwide, multicenter, prospective, observational, cohort study

Jung Gil Park
, Won Young Tak^*
, Soo Young Park
, Young Oh Kweon
, Woo Jin Chung
, Byoung Kuk Jang
, Si Hyun Bae
, Heon Ju Lee
, Jae Young Jang
, Ki Tae Suk
, Myung Jin Oh
, Jeong Heo
, Hyun Young Woo
, Se Young Jang
, Yu Rim Lee
, June Sung Lee
, Do Young Kim
, Seok Hyun Kim
, Jeong Ill Suh
, In Hee Kim

Min Kyu Kang, Won Kee Lee

^*Corresponding author for this work

Department of Medicine

Yeungnam University
Kyungpook National University
Keimyung University
The Catholic University of Korea
Soonchunhyang University
Hallym University
Cha College of Medicine
Pusan National University
Inje University
Yonsei University
Choungnam National University
Dongguk University

Research output: Contribution to journal › Journal article › peer-review

47 Scopus citations

Abstract

Background and Aims: Clinical evidence for the benefits of branched-chain amino acids (BCAAs) is lacking in advanced liver disease. We evaluated the potential benefits of long-term oral BCAA supplementation in patients with advanced liver disease. Methods: Liver cirrhosis patients with Child–Pugh (CP) scores from 8 to 10 were prospectively recruited from 13 medical centers. Patients supplemented with 12.45 g of daily BCAA granules over 6 months, and patients consuming a regular diet were assigned to the BCAA and control groups, respectively. The effects of BCAA supplementation were evaluated using the model for end-stage liver disease (MELD) score, CP score,.

Original language	English
Article number	1429
Journal	Nutrients
Volume	12
Issue number	5
DOIs	https://doi.org/10.3390/nu12051429
State	Published - 2020.05

Quacquarelli Symonds(QS) Subject Topics

Nursing
Agriculture & Forestry

Access to Document

10.3390/nu12051429

Cite this

Park, J. G., Tak, W. Y., Park, S. Y., Kweon, Y. O., Chung, W. J., Jang, B. K., Bae, S. H., Lee, H. J., Jang, J. Y., Suk, K. T., Oh, M. J., Heo, J., Woo, H. Y., Jang, S. Y., Lee, Y. R., Lee, J. S., Kim, D. Y., Kim, S. H., Suh, J. I., ... Lee, W. K. (2020). Effects of branched-chain amino acid (BCAA) supplementation on the progression of advanced liver disease: A korean nationwide, multicenter, prospective, observational, cohort study. Nutrients, 12(5), Article 1429. https://doi.org/10.3390/nu12051429

@article{c1dc24999078410c841b0e59d241fc3a,

title = "Effects of branched-chain amino acid (BCAA) supplementation on the progression of advanced liver disease: A korean nationwide, multicenter, prospective, observational, cohort study",

abstract = "Background and Aims: Clinical evidence for the benefits of branched-chain amino acids (BCAAs) is lacking in advanced liver disease. We evaluated the potential benefits of long-term oral BCAA supplementation in patients with advanced liver disease. Methods: Liver cirrhosis patients with Child–Pugh (CP) scores from 8 to 10 were prospectively recruited from 13 medical centers. Patients supplemented with 12.45 g of daily BCAA granules over 6 months, and patients consuming a regular diet were assigned to the BCAA and control groups, respectively. The effects of BCAA supplementation were evaluated using the model for end-stage liver disease (MELD) score, CP score,.",

author = "Park, \{Jung Gil\} and Tak, \{Won Young\} and Park, \{Soo Young\} and Kweon, \{Young Oh\} and Chung, \{Woo Jin\} and Jang, \{Byoung Kuk\} and Bae, \{Si Hyun\} and Lee, \{Heon Ju\} and Jang, \{Jae Young\} and Suk, \{Ki Tae\} and Oh, \{Myung Jin\} and Jeong Heo and Woo, \{Hyun Young\} and Jang, \{Se Young\} and Lee, \{Yu Rim\} and Lee, \{June Sung\} and Kim, \{Do Young\} and Kim, \{Seok Hyun\} and Suh, \{Jeong Ill\} and Kim, \{In Hee\} and Kang, \{Min Kyu\} and Lee, \{Won Kee\}",

note = "Publisher Copyright: {\textcopyright} 2020 by the authors. Licensee MDPI, Basel, Switzerland.",

year = "2020",

month = may,

doi = "10.3390/nu12051429",

language = "English",

volume = "12",

journal = "Nutrients",

issn = "2072-6643",

number = "5",

}

Park, JG, Tak, WY, Park, SY, Kweon, YO, Chung, WJ, Jang, BK, Bae, SH, Lee, HJ, Jang, JY, Suk, KT, Oh, MJ, Heo, J, Woo, HY, Jang, SY, Lee, YR, Lee, JS, Kim, DY, Kim, SH, Suh, JI, Kim, IH, Kang, MK & Lee, WK 2020, 'Effects of branched-chain amino acid (BCAA) supplementation on the progression of advanced liver disease: A korean nationwide, multicenter, prospective, observational, cohort study', Nutrients, vol. 12, no. 5, 1429. https://doi.org/10.3390/nu12051429

TY - JOUR

T1 - Effects of branched-chain amino acid (BCAA) supplementation on the progression of advanced liver disease

T2 - A korean nationwide, multicenter, prospective, observational, cohort study

AU - Park, Jung Gil

AU - Tak, Won Young

AU - Park, Soo Young

AU - Kweon, Young Oh

AU - Chung, Woo Jin

AU - Jang, Byoung Kuk

AU - Bae, Si Hyun

AU - Lee, Heon Ju

AU - Jang, Jae Young

AU - Suk, Ki Tae

AU - Oh, Myung Jin

AU - Heo, Jeong

AU - Woo, Hyun Young

AU - Jang, Se Young

AU - Lee, Yu Rim

AU - Lee, June Sung

AU - Kim, Do Young

AU - Kim, Seok Hyun

AU - Suh, Jeong Ill

AU - Kim, In Hee

AU - Kang, Min Kyu

AU - Lee, Won Kee

PY - 2020/5

Y1 - 2020/5

N2 - Background and Aims: Clinical evidence for the benefits of branched-chain amino acids (BCAAs) is lacking in advanced liver disease. We evaluated the potential benefits of long-term oral BCAA supplementation in patients with advanced liver disease. Methods: Liver cirrhosis patients with Child–Pugh (CP) scores from 8 to 10 were prospectively recruited from 13 medical centers. Patients supplemented with 12.45 g of daily BCAA granules over 6 months, and patients consuming a regular diet were assigned to the BCAA and control groups, respectively. The effects of BCAA supplementation were evaluated using the model for end-stage liver disease (MELD) score, CP score,.

AB - Background and Aims: Clinical evidence for the benefits of branched-chain amino acids (BCAAs) is lacking in advanced liver disease. We evaluated the potential benefits of long-term oral BCAA supplementation in patients with advanced liver disease. Methods: Liver cirrhosis patients with Child–Pugh (CP) scores from 8 to 10 were prospectively recruited from 13 medical centers. Patients supplemented with 12.45 g of daily BCAA granules over 6 months, and patients consuming a regular diet were assigned to the BCAA and control groups, respectively. The effects of BCAA supplementation were evaluated using the model for end-stage liver disease (MELD) score, CP score,.

UR - https://www.scopus.com/pages/publications/85084964977

U2 - 10.3390/nu12051429

DO - 10.3390/nu12051429

M3 - Journal article

C2 - 32429077

AN - SCOPUS:85084964977

SN - 2072-6643

VL - 12

JO - Nutrients

JF - Nutrients

IS - 5

M1 - 1429

ER -

Effects of branched-chain amino acid (BCAA) supplementation on the progression of advanced liver disease: A korean nationwide, multicenter, prospective, observational, cohort study

Abstract

Quacquarelli Symonds(QS) Subject Topics

Access to Document

Other files and links

Fingerprint

Cite this